-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BMO Capital Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $52

Benzinga · 01/06/2023 08:16
BMO Capital analyst Gary Nachman maintains Pacira BioSciences (NASDAQ:PCRX) with a Market Perform and lowers the price target from $60 to $52.